Sigma Planning’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IBRX
Sigma Planning's IBRX Position: Q3 2026 in Review
Sigma Planning increased its ImmunityBio (IBRX) stake by 5.8% in Q3 2026, buying an estimated $8.79K and bringing the position to 20,115 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #1264.
Sigma Planning first reported a position in IBRX in Q1 2022 and has held it in 18 quarters since. 321 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.
- Sigma Planning held 20,115 shares of ImmunityBio worth $190K as of Q3 2026.
- Sigma Planning bought 1,100 ImmunityBio shares in Q3 2026, an estimated $8.79K.
- ImmunityBio made up ﹤0.01% of Sigma Planning's portfolio in Q3 2026, its #1264 holding.
- Sigma Planning first reported a position in ImmunityBio in Q1 2022 and has held it in 18 quarters since.
- 321 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.
Based on Sigma Planning's 13F filing for Q3 2026, filed 23 Oct 2026.